대장암 검사 및 진단 시장 : 세계 및 지역별 분석 - 유형별, 최종사용자별, 지역별, 경쟁 환경, 가격 분석, 검사량 분석 및 예측(2023-2033년)
Colorectal Cancer Screening and Diagnostics Market - A Global and Regional Analysis: Focus on Type, End User, Region, and Competitive Landscape, Pricing Analysis, Testing Volume - Analysis and Forecast, 2023-2033
상품코드:1452914
리서치사:BIS Research
발행일:2024년 03월
페이지 정보:영문
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
대장암 검사 및 진단 시장 규모는 2022년 371억 4,580만 달러에서 예측 기간 동안 2.37%의 연평균 복합 성장률(CAGR)을 나타내고, 2033년에는 487억 1,090만 달러 규모로 성장할 것으로 예측됩니다.
이러한 성장의 배경에는 대장암 발병률 증가와 의료비 부담 증가, 대장암 검사에 대한 수요 증가, 유전체학 및 분자진단의 발전, 치료 비용을 절감할 수 있는 암 조기 발견의 촉진 등이 있습니다.
주요 시장 통계
예측 기간
2023-2033년
2023년 평가액
385억 4,000만 달러
2033년 전망
487억 1,000만 달러
CAGR
2.37%
대장 내시경과 S자 결장 내시경이 시장을 독점하고 있습니다.
유형별로는 대장내시경과 S형 결장 내시경 부문이 2022년 시장을 장악했습니다. 대장 내시경 검사는 결장과 직장 전체를 자세히 검사할 수 있어 암뿐만 아니라 전암성 용종도 발견할 수 있으며, S상 결장 내시경 검사는 결장의 하부만 검사하기 때문에 범위가 제한되어 있어 검사 노력에 중요한 역할을 하고 있습니다.
최종 사용자별로는 병원 및 진료소 부문이 우위를 점하고 있습니다.
최종 사용자별로는 병원 및 클리닉 부문이 2022년 시장에서 가장 큰 점유율을 차지했는데, 이는 첨단 진단 장비와 전문 의료 서비스 제공 등의 종합적인 의료 서비스를 통해 대장암을 조기에 발견하고 관리할 수 있기 때문입니다.
북미는 세계 시장의 선두주자이며, 향후 몇 년동안 그 지위를 유지할 것으로 예상됩니다. 이러한 우위는 대장암에 대한 높은 인식 수준, 미국 및 캐나다 전역에 걸친 종합적인 검사 프로그램 시행 등 몇 가지 중요한 요인에 기인합니다.
세계 대장암 검사 및 진단 시장을 조사했으며, 시장 개요, 주요 동향, 기술 및 특허 동향, 제품 파이프라인, 규제 환경, 시장 영향요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다. 주요 기업 프로파일 등을 정리하여 전해드립니다.
목차
주요 요약
제1장 시장
동향 : 현재 및 향후 영향 평가
재택 대장암검사 부상
대장암 검사에의 복합적 접근
대장암 진단 장내 미생물총 이용
R&D 리뷰
특허 출원 동향(국가/연도별)
주요 세계 이벤트의 영향 분석 : COVID-19
제품 파이프라인
규제 상황
다양한 국가 및 지역의 상환 시나리오
다양한 지역에서의 다양한 테스트 유형 가격 분석
시장 역학 개요
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
제2장 용도
용도 분류
용도 개요
용도 개요
최종사용자 개요
세계의 대장암 검사 및 진단 시장(최종사용자별)
개요
병원 및 진료소
외래 센터
임상실험실
기타
제3장 제품
제품 분류
제품 개요
애널리스트 관점
세계의 대장암 검사 및 진단 시장(유형별)
시장 개요
대변 DNA 검사
Fecal Immunochemical Test (FIT)
Fecal Occult Blood Test (FOBT)
대장 내시경 및 S상 결장경
바이오마커 검사
제4장 지역
지역 개요
성장 촉진요인 및 억제요인
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
제5장 시장 : 경쟁 벤치마킹 및 기업 개요
Next Frontiers
지역적 평가
DiaCarta, Inc.
Danaher Corporation
Epigenomics AG
Eiken Chemical Co., Ltd.
Exact Sciences Corporation
Freenome Holdings, Inc.
FUJIFILM Holdings Corporation
Guardant Health, Inc.
Lepu Medical Technology(Beijing) Co., Ltd.
Mainz Biomed NV
New Horizon Health
Novigenix SA
Prenetics Global Limited
Olympus Corporation
HOYA Corporation
QuidelOrtho Corporation
제6장 조사 방법
LSH
영문 목차
영문목차
Global Colorectal Cancer Screening and Diagnostics Market Overview
The global colorectal cancer screening and diagnostics market is projected to experience substantial growth over the forecast period 2023-2033. Moreover, the market value for 2022 was $37,145.8 million, which is expected to reach $48,710.9 million by 2033, growing at a CAGR of 2.37% during the forecast period. This growth can be attributed to the rising incidence of colorectal cancer and increasing financial burden on healthcare, growing demand for colorectal cancer testing, advances in genomics and molecular diagnostics, and promoting early cancer detection to enable reduced treatment costs. The market includes various types of tests, such as stool DNA tests, fecal immunochemical tests, fecal occult blood tests, biomarker tests, colonoscopies, and sigmoidoscopies.
Market Lifecycle Stage
KEY MARKET STATISTICS
Forecast Period
2023 - 2033
2023 Evaluation
$38.54 Billion
2033 Forecast
$48.71 Billion
CAGR
2.37%
The colorectal cancer screening and diagnostics market is currently at a growing stage with a robust growth trajectory, propelled by the rising demand for at-home colorectal cancer screening and diagnostics. The market is characterized by a mix of well-established companies and innovative startups, all competing to offer advanced solutions that cater to the evolving demands of research and diagnostics.
Industry Impact
The global colorectal cancer screening and diagnostics market's impact is profound and multifaceted, influencing healthcare practices, patient outcomes, and economic dynamics within the healthcare sector. The market's growth is driving a significant shift toward early detection and prevention, leading to improved survival rates and quality of life for patients. This shift is also catalyzing a transition in healthcare focus from treatment to prevention, encouraging the development of public health policies and insurance coverage that support regular screening.
Economically, the expansion of the colorectal cancer screening and diagnostics market has been contributing to the healthcare industry's growth, owing to increased investments in research and development of more accurate and less invasive screening technologies. These innovations not only enhance patient compliance and comfort but also have the potential to reduce long-term healthcare costs by preventing advanced disease stages that require more intensive and expensive treatments.
The global colorectal cancer screening and diagnostics market continues to drive transformative advancements across industries, with far-reaching implications for human health and environmental sustainability.
Market Segmentation
Segmentation 1: by Type
Stool DNA Test
Fecal Immunochemical Test (FIT)
Fecal Occult Blood Test (FOBT)
Colonoscopies and Sigmoidoscopies
Biomarkers Test
Colonoscopies and Sigmoidoscopies to Dominate the Global Colorectal Cancer Screening and Diagnostics Market (by Type)
Based on type, the colonoscopies and sigmoidoscopies segment dominated the global colorectal cancer screening and diagnostics market in FY2022. This category includes colonoscopes and sigmoidoscopes, which are considered a gold standard for diagnosis and screening for colorectal cancer. Colonoscopy allows for a detailed examination of the entire colon and rectum, enabling the detection of not only cancers but also precancerous polyps, which can be removed during the same procedure to prevent cancer development. Sigmoidoscopy, while more limited in scope, examining only the lower part of the colon, still plays a crucial role in screening efforts, especially in cases where a full colonoscopy might not be necessary or feasible.
Segmentation 2: by End User
Hospitals and Clinics
Ambulatory Centers
Clinical Laboratories
Others
Hospitals and Clinics Segment to Hold its Dominance in the Global Colorectal Cancer Screening and Diagnostics Market (by End User)
Based on end user, the hospitals and clinics accounted for the largest share of the global colorectal cancer screening and diagnostics market in FY2022 due to the comprehensive healthcare services offered by them, including advanced diagnostic facilities and the availability of specialized care, which enable early detection and management of colorectal cancer.
Segmentation 3: by Region
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
The North America region is a leader in the global colorectal cancer screening and diagnostics market, a position it is expected to maintain over the coming years. This dominance can be attributed to several key factors, including high awareness levels regarding colorectal cancer, and the implementation of comprehensive screening programs across the U.S. and Canada.
Recent Developments in the Global Colorectal Cancer Screening and Diagnostics Market
In February 2024, Exact Sciences Corporation announced gearing up for the launch of a new slate of assays over the next few years, including a new iteration of its well-established stool-based colorectal cancer screening test, Cologuard, a complementary blood-based assay and a test for minimal residual disease detection.
In February 2024, Freenome Holdings, Inc. announced that it raised $254 million in a new funding round led by Swiss drugmaker Roche to develop tests that could potentially detect multiple early-stage cancers and is currently developing screening tests focused on colorectal and lung cancers.
In May 2023, Guardant Health collaborated with the Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence.
In May 2023, Guardant Health submitted a premarket approval application to the U.S. Food and Drug Administration for a Shield blood test.
In April 2023, Mainz Biomed revealed a collaboration with the Instituto de Microecologia aimed at broadening ColoAlert's commercial reach in both Spain and Portugal.
In May 2023, Olympus Corporation introduced the CF-HQ1100DL/I colon videoscope, a device specifically created for the inspection of the lower digestive system, covering areas such as the anus, rectum, sigmoid colon, colon, and ileocecal valve. This launch would serve to enhance Olympus's range of products within the colorectal cancer screening and diagnostics sector.
Demand - Drivers, Restraints, and Opportunities
Market Demand Drivers:
Rising Incidence of Colorectal Cancer and Increasing Financial Burden on Healthcare: The increasing healthcare expenditure related to colorectal cancer reflects the growing costs associated with its prevention, diagnosis, treatment, and management. As the incidence of colorectal cancer rises, the economic burden of the disease is also increasing. These costs include direct medical costs such as hospitalization, surgery, chemotherapy, and radiation therapy.
Market Restraints:
Limited Sensitivity of FIT/FOBT Testing Kits: While non-invasive testing techniques for colorectal cancer, such as fecal immunochemical tests and stool DNA tests, have shown significant potential in cancer detection, they do have some limitations. One of the major limitations is their limited sensitivity, meaning they may not detect all cases of colorectal cancer, particularly in the early stages. This can result in false negatives and delayed diagnosis, which can impact patient outcomes.
Market Opportunities:
Expansion of Screening Programs: Population-wide screening programs are proving to be a lucrative opportunity for the colorectal cancer screening and diagnostic market by leading to an increased number of individuals being screened for colorectal cancer, leading to earlier detection and treatment of the disease. By improving access to screening, these programs can also reduce healthcare costs and improve patient outcomes associated with more advanced stages of the disease, thereby resulting in a strong interest in these testing methodologies by various government and NGO screening programs.
How can this report add value to an organization?
Workflow/Innovation Strategy: The global colorectal cancer screening and diagnostics market (by product) has been segmented into detailed segments, including different types of tests, such as fecal immunochemical tests, fecal occult tests, stool DNA tests, biomarker tests, and colonoscopies and sigmoidoscopies.
Growth/Marketing Strategy: A strategic growth and marketing approach for the colorectal cancer screening and diagnostics market would involve positioning the company as a leader in innovative solutions that address the evolving needs of hospitals, clinicians, laboratories, and pharmaceutical partners. This would entail leveraging technological advancements to develop products with enhanced sensitivity and specificity while also investing in comprehensive, collaborative partnerships to foster customer loyalty and drive market penetration.
Competitive Strategy: Key players in the global colorectal cancer screening and diagnostics market have been focusing on innovation, differentiation, and strategic collaborations to gain a competitive edge. By investing in research and development, companies can develop novel screening and diagnostics methods, improve test sensitivity, and expand application areas.
Methodology
Key Considerations and Assumptions in Market Engineering and Validation
The base year considered for the calculation of the market size is 2022. The historical year analysis has been done from FY2020 to FY2021, and the market size has been calculated for FY2022 and projected for the period 2023-2033.
The geographical distribution of the market revenue has been estimated to be the same as the company's net revenue distribution. All the numbers have been adjusted to two digits after decimals for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. CAGR has been calculated from 2023 to 2033.
The market has been mapped based on different types of products available in the market and based on several indications. All the key manufacturing companies that have a significant number of types of tests for the global colorectal cancer screening and diagnostics market have been considered and profiled in the report.
In the study, the primary respondent's verification has been considered to finalize the estimated market for the global colorectal cancer screening and diagnostics market.
The latest annual reports of each market player have been taken into consideration for market revenue calculation.
Market strategies and developments of key players have been considered for the calculation of sub-segment split.
The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website or from the annual reports of the respective company, if stated.
Primary Research
The key data points taken from the primary sources include:
Validation and triangulation of all the numbers and graphs
Validation of the report's segmentation and key qualitative findings
Understanding of the numbers of the various markets for market type
Percentage split of individual markets for regional analysis
Secondary Research
Open Sources
National Center for Biotechnology Information (NCBI), PubMed, Science Direct, World Bank Group, and World Health Organization (WHO)
Annual reports, SEC filings, and investor presentations of the leading market players
Company websites and detailed study of their portfolio
Gold standard magazines, journals, whitepapers, press releases, and news articles
Databases
The key data points taken from the secondary sources include:
Segmentations, split-ups, and percentage shares
Data for market value
Key industry trends of the top players in the market
Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
Quantitative data for mathematical and statistical calculations
Key Market Players and Competition Synopsis
In the colorectal cancer screening and diagnostics market, several key players dominate the landscape with their diverse range of products and solutions. Exact Sciences Corporation, Danaher Corporation, Guardant Health, Inc., Mainz Biomed NV, and New Horizon Health are among the prominent market players offering tests and colonoscopies and sigmoidoscopies for colorectal cancer screening and diagnostics within the market.
The competition in the colorectal cancer screening and diagnostics market has been characterized by a dynamic and intensely competitive landscape with a variety of market players. This competition has been further fuelled by factors such as technological advancements, increasing demand for early detection methods, and the presence of numerous companies offering innovative solutions and services in this field.
Some of the prominent companies in this market are:
DiaCarta, Inc.
Danaher Corporation
Epigenomics AG
Eiken Chemical Co., Ltd.
Exact Sciences Corporation
Freenome Holdings, Inc.
FUJIFILM Holdings Corporation
Guardant Health, Inc.
Lepu Medical Technology (Beijing) Co., Ltd.
Mainz Biomed NV
New Horizon Health
Novigenix SA
Prenetics Global Limited
Olympus Corporation
HOYA Corporation
QuidelOrtho Corporation
Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).
Table of Contents
Executive Summary
Scope and Definition
1 Markets
1.1 Trends: Current and Future Impact Assessment
1.1.1 Rise of At-Home Colorectal Cancer Screening
1.1.2 Multimodal Approaches to Colorectal Cancer Screening
1.1.3 Use of Gut Microbiota in Colorectal Cancer Diagnosis
1.2 Research and Development Review
1.2.1 Patent Filing Trend (by Country, by Year)
1.3 Impact Analysis for Key Global Events: COVID-19
1.3.1 Pre-COVID-19 Phase
1.3.2 During-COVID-19 Phase
1.3.3 Post-COVID-19 Phase
1.4 Product Pipeline
1.5 Regulatory Landscape
1.6 Reimbursement Scenarios in Different Countries and Regions
1.6.1 Stool DNA Test
1.6.2 Fecal Immunochemical Test (FIT)
1.6.3 Fecal Occult Blood Test (FOBT)
1.6.4 Colonoscopies and Sigmoidoscopies
1.6.5 Biomarker Tests
1.7 Pricing Analysis for Different Test Types in Different Regions
1.8 Market Dynamics Overview
1.8.1 Market Drivers
1.8.1.1 Rising Incidence of Colorectal Cancer and Increasing Financial Burden on Healthcare
1.8.1.2 Growing Demand for Colorectal Cancer Testing
1.8.1.3 Advances in Genomics and Molecular Diagnostics
1.8.1.4 Earlier Cancer Detection Enabling Reduced Treatment Cost
1.8.2 Market Restraints
1.8.2.1 Limited Sensitivity of FIT/FOBT Testing Kits
